Riskpilot← Back to searchSign inGet full accessOSTOMYCURE AS
ASActiveOrg 986039252Dokkveien 1, 0250 OsloManufacture of medical and dental instruments and supplies · NACE 3250Est. 20030 employeesostomycure.com
Revenue 2024
NOK 0
EBITDA margin
—
+12% vs 2023
Equity ratio
59.8%
Financial strength
Net profit 2024
NOK -12,9M
+23% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -11,5M | +12% |
| Net profit | NOK -12,9M | +23% |
| Total assets | NOK 42,2M | +85% |
| Equity | NOK 25,3M | +991% |
| Employees | 0 | — |
Legal name
OSTOMYCURE AS
Org number
986039252
Legal form
Aksjeselskap
NACE code
3250 · Manufacture of medical and dental instruments and supplies
Founded
15. september 2003
Share capital
NOK 498 972
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Utvikling, produksjon og salg av medisinsk utstyr og annet tilhørende.
Address
Dokkveien 1, 0250 Oslo
Website
ostomycure.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3 040 | 502 | 872 | 181 | 1 567 | 3 608 | 1 876 | 2 101 | 2 924 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −3 363 | −2 760 | −2 737 | −3 137 | −2 509 | 53 | −2 | −0 | −4 | −1 473 | −117 | −1 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −8 381 | −7 353 | −7 657 | −10 223 | −7 310 | −3 294 | −3 199 | −4 141 | −7 521 | −16 673 | −17 979 | −2 650 | −6 453 | −7 927 | −13 404 | −13 098 | −11 505 |
| Depreciation & amort. | −14 | −14 | −12 | −0 | −0 | −0 | −0 | −0 | −1 | −22 | −22 | −21 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −8 394 | −7 367 | −7 670 | −10 223 | −7 310 | −3 294 | −3 199 | −4 141 | −7 521 | −16 695 | −18 001 | −2 671 | −6 453 | −7 927 | −13 404 | −13 098 | −11 505 |
| Net financials | 93 | 72 | −465 | 75 | 88 | 88 | 17 | 12 | 3 | −2 | −836 | −677 | −1 173 | 346 | −1 114 | −3 629 | −1 435 |
| Profit before tax | −8 301 | −7 295 | −8 134 | −10 148 | −7 222 | −3 207 | −3 182 | −4 129 | −7 518 | −16 697 | −18 837 | −3 348 | −7 626 | −7 581 | −14 518 | −16 727 | −12 940 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −8 301 | −7 295 | −8 134 | −10 148 | −7 222 | −3 207 | −3 182 | −4 129 | −7 518 | −16 697 | −18 837 | −3 348 | −7 626 | −7 581 | −14 518 | −16 727 | −12 940 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 3 331 | 4 005 | 4 614 | 6 800 | 4 046 | 3 746 | 2 146 | 1 856 | 6 387 | 12 378 | 22 719 | 16 418 | 21 118 | 22 435 | 23 274 | 22 835 | 42 219 |
| Equity | 856 | 2 495 | −5 640 | 4 973 | −2 249 | −5 456 | 426 | 755 | −640 | −17 337 | −36 174 | 3 636 | 7 736 | 7 917 | −6 601 | −2 835 | 25 260 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2 475 | 1 511 | 10 253 | 1 827 | 6 296 | 9 202 | 1 720 | 1 101 | 7 027 | 29 715 | 58 893 | 12 782 | 13 382 | 14 517 | 29 875 | 25 670 | 16 959 |
| Total debt | 2 475 | 1 511 | 10 253 | 1 827 | 6 296 | 9 202 | 1 720 | 1 101 | 7 027 | 29 715 | 58 893 | 12 782 | 13 382 | 14 517 | 29 875 | 25 670 | 16 959 |
EBITDA margin
-1150543800.0%
This company
15.8%
Market median
-7281922885% vs market
20082024
Equity ratio
59.8%
This company
38.2%
Market median
+57% vs market
20082024
Return on equity
-51.2%
This company
18.4%
Market median
-378% vs market
20082024
Net profit margin
-1294038800.0%
This company
8.1%
Market median
-15975787754% vs market
20082024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20082024
Debt / equity
0.67×
This company
0.62×
Market median
+8% vs market
20082024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JJ Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
JN Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2026 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Kistefos As | Company | 70.4% | 70.4% | 2024 |
Canica As | Company | 15.6% | 15.6% | 2024 |
Pega Ehf | Company | 5.1% | 5.1% | 2024 |
Adalbol Fasteigir Hf | Company | 1.3% | 1.3% | 2024 |
Monolitten Invest As | Company | 1.2% | 1.2% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of OSTOMYCURE AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Johan Jaerte | Chief Executive Officer | 0 companies |
| Johan Nils Otto Järte | Chief Executive Officer | 0 companies |
| Manish Kumar Chand | Board of Directors | 0 companies |
| Lars Magnus Mikkelsen | Board of Directors | 0 companies |
| Georg Stang | Board of Directors | 0 companies |
| William Wilson Rutan | Board of Directors | 0 companies |
| Henriette Andrea Stead Gjefle | Board of Directors | 0 companies |
| Graeme Lawrence Smith | Chairman | 0 companies |
| Martin Alexander Krekling | Board of Directors | 0 companies |
| Nishant Bhavik Vicky Fafalia | Chairman | 0 companies |
| Lars Petter Ottem Utseth | Board of Directors | 0 companies |
| Johan Frederik Blichfeldt Gjesdahl | Board of Directors | 0 companies |